UNITED ~~STATES SECURITIES~~STATESSECURITIES AND EXCHANGE ~~COMMISSION Washington~~COMMISSIONWashington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of ~~December~~January ~~2025~~2026

Commission File Number: 001-39179

Addex Therapeutics Ltd(Translation of registrant's name into English)

Chemin des Mines 9, CH-1202 Geneva, Switzerland(~~Translation~~Address of ~~registrant's~~principal ~~name~~executive ~~into English~~office)

~~Chemin~~Indicate ~~des~~by ~~Mines~~check ~~9, CH-1202~~mark ~~Geneva, Switzerland (Address~~whether the registrant files or will file annual reports under cover of ~~principal~~Form ~~executive~~20-F ~~office)~~or Form 40-F.Form 20-F [ X ] Form 40-F [ ]

~~Indicate~~On byJanuary ~~check~~7, ~~mark~~2026, ~~whether~~ the ~~registrant~~Registrant ~~files~~issued ora ~~will~~press ~~file~~release, ~~annual reports~~a ~~under~~copy ~~cover~~ of ~~Form 20-F~~which oris ~~Form 40-F~~attached hereto as Exhibit 99.1 and is incorporated herein by reference.

~~Form 20-F~~(c) ~~x Form 40-F ¨~~Exhibit 99.1. Press release dated January 7, 2026

INCORPORATION BY REFERENCE

~~This~~Exhibit ~~report~~99.1 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration ~~statements~~statement on Form F-3 (Registration No. 333-291644) of Addex Therapeutics Ltd and the registration statement on Form S-8 (~~Nos~~Registration No. 333-~~272515~~ 255124 and No. 333-~~255124~~272515), of Addex Therapeutics Ltd (~~the “Company”) (~~including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

~~Entry~~RISK ~~into Amendment to At The Market Offering Agreement with H.C. Wainwright & Co., LLC~~FACTORS

AsOur ~~previously~~business ~~disclosed,~~faces ~~on January 30,~~significant ~~2024,~~risks. ~~the~~You ~~Company~~should ~~entered~~carefully ~~into~~consider anall Atof ~~The Market Offering Agreement (~~the ~~“Original~~information ~~ATM Agreement”)~~set ~~with~~forth ~~H.C.~~in ~~Wainwright &~~this ~~Co.,~~Report ~~LLC~~on ~~(“H.C.~~Form ~~Wainwright”)~~6-K ~~with~~and ~~respect~~in ~~to an at-the-market offering~~our ~~program~~other ~~under~~filings ~~which~~with the ~~Company~~United ~~may~~States ~~offer~~Securities and ~~sell,~~Exchange ~~from time to time at its sole discretion~~Commission, ~~the~~ ~~Company’s~~or ~~American Depositary Shares (~~the ~~“ADSs”)~~SEC, ~~each~~including ~~representing~~the ~~one~~risk ~~hundred~~factors ~~and~~related ~~twenty~~to ~~ordinary shares~~our ~~(nominal~~business ~~value~~set ~~CHF~~forth ~~0.01~~in ~~per~~our ~~share)~~Annual ~~(the~~Report ~~“Ordinary~~on ~~Shares”)~~Form ~~through~~20-F ~~H.C.~~for ~~Wainwright~~the asyear ~~its~~ended ~~sales agent. On~~ December 1031, ~~2025,~~2024 ~~the~~filed ~~Company~~with ~~entered~~the ~~into~~Securities ~~Amendment~~and ~~No.~~Exchange 1Commission toon ~~the~~May ~~Original~~15, ~~ATM~~2025. ~~Agreement~~Our ~~(as amended~~business, ~~the~~financial ~~“ATM Agreement”)~~condition, Asresults of ~~the~~operations ~~date~~and ~~hereof,~~growth ~~the~~prospects ~~Company~~could ~~filed~~be ~~a prospectus~~materially ~~supplement~~adversely toaffected ~~increase~~by ~~the~~any ~~maximum~~of ~~number~~these ofrisks. ~~Ordinary~~This ~~Shares~~report ~~issuable~~also ~~pursuant~~contains toforward-looking ~~the~~statements ~~ATM~~that ~~Agreement,~~involve ~~having~~risks anand ~~aggregate~~uncertainties. ~~offering~~Our ~~price~~results ofcould upmaterially todiffer ~~$3.3~~from ~~million.~~those ~~The~~anticipated ~~issuance~~in ~~and sale,~~these ifforward-looking ~~any~~statements, ofas ~~the~~a ~~ADSs~~result byof ~~the~~certain ~~Company~~factors ~~under~~including the ~~ATM~~risks ~~Agreement~~described ~~will~~in beour ~~made~~Annual ~~pursuant~~Report toand ~~the~~our ~~Company’s~~other ~~effective~~SEC ~~registration statement on Form F-3 (Registration Statement No~~filings. ~~333-291644).~~

H.C. Wainwright may sell the ADSs by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended, including, without limitation, sales made through The Nasdaq Capital Market or on any other existing trading market for the ADSs. H.C. Wainwright will use commercially reasonable efforts to sell the ADSs from time to time, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company will pay H.C. Wainwright a commission equal to three percent (3.0%) of the gross sales proceeds of any ADSs sold through H.C. Wainwright under the ATM Agreement, and also has provided H.C. Wainwright with customary indemnification and contribution rights.

The Company is not obligated to make any sales of ADSs under the ATM Agreement. The Company or H.C. Wainwright may suspend or terminate the offering of ADSs upon notice to the other party and subject to other conditions. H.C. Wainwright will act as sales agent on a commercially reasonable efforts basis consistent with its normal trading and sales practices and applicable state and federal law, rules and regulations and the rules of the Nasdaq Stock Market.

The foregoing description of the ATM Agreement is not complete and is qualified in its entirety by reference to the full text of the ATM Agreement, a copy of which is filed in part as Exhibit 1.1 to the Company’s report on Form 6-K filed on January 30, 2024 and in part herewith as Exhibit 1.1 to this report on Form 6-K and is incorporated herein by reference. A copy of the legal opinion of Homburger AG, the Company’s Swiss counsel, relating to the underlying shares issued in connection with the ATM Agreement is attached as Exhibit 5.1 hereto.

This report on Form 6-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any offer, solicitation, or sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

EXHIBIT INDEX

Exhibit Number		Description
1.1		Amendment No. 1 to At The Market Offering Agreement, dated as of December 10, 2025, by and between Addex Therapeutics Ltd and H.C. Wainwright & Co., LLC.
5.1		Opinion of Homburger AG
23.1		Consent of Homburger AG (included in Exhibit 5.1)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	~~Addex Therapeutics Ltd~~	Addex Therapeutics Ltd
	~~(Registrant)~~	(Registrant)
Date: December 10, 2025	/s/ Tim Dyer
Date: January 7, 2026		/s/ Tim Dyer
	~~Tim Dyer~~	Tim Dyer
	~~Chief Executive Officer~~	Chief Executive Officer

EXHIBIT INDEX

Exhibit Number		Description

99.1		Press release dated January 7, 2026

Filing Compare · Addex Therapeutics Ltd.